Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Non-Current Assets (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Non-Current Assets for 6 consecutive years, with $106.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Assets changed N/A year-over-year to $106.4 million, compared with a TTM value of -$555.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of $103.1 million, up 0.64% over the prior year.
  • Non-Current Assets was $106.4 million for Q3 2025 at Cytek Biosciences, up from -$380.5 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $106.4 million in Q3 2025 and bottomed at -$384.1 million in Q2 2024.
  • Average Non-Current Assets over 5 years is -$13.4 million, with a median of $15.0 million recorded in 2021.
  • The sharpest move saw Non-Current Assets skyrocketed 1172.07% in 2022, then tumbled 483.19% in 2024.
  • Year by year, Non-Current Assets stood at $5.9 million in 2021, then soared by 133.84% to $13.7 million in 2022, then skyrocketed by 648.41% to $102.4 million in 2023, then increased by 0.64% to $103.1 million in 2024, then grew by 3.28% to $106.4 million in 2025.
  • Business Quant data shows Non-Current Assets for CTKB at $106.4 million in Q3 2025, -$380.5 million in Q1 2025, and $103.1 million in Q4 2024.